Candel Therapeutics, Inc.
Candel Therapeutics, Inc. scores highest on Nitro (62) and lowest on Price (14). Its PosiPenta is 40.79 out of 100, around the middle of similar companies.
On the Penta Grid this week, Candel Therapeutics, Inc. is Grid #514 of 837 in the Healthcare sector in United States, and Grid #2,814 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Candel Therapeutics, Inc. | 40.79 | 14 | 50 | 62 | 34 | 44 |
| Pacific Biosciences of California, Inc. | 28.28 | 0 | 44 | 52 | 2 | 44 |
| OrthoPediatrics Corp. | 55.20 | 32 | 49 | 81 | 53 | 62 |
| Arbutus Biopharma Corporation | 66.02 | 67 | 44 | 72 | 85 | 63 |
| CorMedix Inc. | 58.56 | 80 | 47 | 50 | 67 | 49 |
| Ginkgo Bioworks Holdings, Inc. | 39.65 | 32 | 33 | 60 | 30 | 43 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -5.61 |
| P/B ratio | 4.97 |
EEarnings
| Trailing EPS | ₹-138.28 |
| Forward EPS | ₹-59.20 |
NNitro
| Price | 775.72 |
| 52-week high | 1326.01 |
| 52-week low | 412.01 |
| Fall from 52-week high | 41.5% |
TTorque
| Return on equity (ROE) | -81.84% |
| Debt-to-equity | 0.39 |
AAnchor
| Beta (price swings) | -0.31 |
| Market cap | ₹5,935 Cr |
| Insider holding | 14.65% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Candel Therapeutics, Inc.'s PosiPenta score?
Candel Therapeutics, Inc.'s PosiPenta is 40.79 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Candel Therapeutics, Inc. stand on the Penta Grid?
On the Penta Grid this week, Candel Therapeutics, Inc. is Grid #514 of 837 in the Healthcare sector in United States, and Grid #2,814 of 4,000 in United States.
Which PosiPenta pillar is strongest for Candel Therapeutics, Inc.?
Nitro (momentum), with a score of 62 out of 100: better than most similar companies.
Which PosiPenta pillar is weakest for Candel Therapeutics, Inc.?
Price (valuation), with a score of 14 out of 100: much weaker than most similar companies.
Has Candel Therapeutics, Inc.'s PosiPenta changed since last week?
Yes, it rose 2.14 points, from 38.65 to 40.79.
PositoAI is for research and education only and is not investment advice.